A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s diseaseStephen Salloway, Paul Aisen, Anna Santacruz et al.|Nature Medicine|2021Cited by 365
Agonist-Induced Phosphorylation of the Angiotensin AT1a Receptor Is Localized to a Serine/Threonine-Rich Region of Its Cytoplasmic TailRoger Smith, Kevin Catt, László Hunyady et al.|Molecular Pharmacology|1998Cited by 74
Alternative splicing in a presenilin 2 variant associated with Alzheimer diseaseJacquelyn E. Braggin, Suman Jayadev|Annals of Clinical and Translational Neurology|2019Cited by 44
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J. Bateman, Bruno Dubois, Yan Li et al.|The Lancet Neurology|2025Cited by 39